157 related articles for article (PubMed ID: 34593527)
1. A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.
Yu S; Wei S; Savani M; Lin X; Du K; Mender I; Siteni S; Vasilopoulos T; Reitman ZJ; Ku Y; Wu D; Liu H; Tian M; Chen Y; Labrie M; Charbonneau CM; Sugarman E; Bowie M; Hariharan S; Waitkus M; Jiang W; McLendon RE; Pan E; Khasraw M; Walsh KM; Lu Y; Herlyn M; Mills G; Herbig U; Wei Z; Keir ST; Flaherty K; Liu L; Wu K; Shay JW; Abdullah K; Zhang G; Ashley DM
Clin Cancer Res; 2021 Dec; 27(24):6800-6814. PubMed ID: 34593527
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Wei S; Yin D; Yu S; Lin X; Savani MR; Du K; Ku Y; Wu D; Li S; Liu H; Tian M; Chen Y; Bowie M; Hariharan S; Waitkus M; Keir ST; Sugarman ET; Deek RA; Labrie M; Khasraw M; Lu Y; Mills GB; Herlyn M; Wu K; Liu L; Wei Z; Flaherty KT; Abdullah K; Zhang G; Ashley DM
Clin Cancer Res; 2022 May; 28(10):2180-2195. PubMed ID: 35247901
[TBL] [Abstract][Full Text] [Related]
3. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
Sengupta S; Sobo M; Lee K; Senthil Kumar S; White AR; Mender I; Fuller C; Chow LML; Fouladi M; Shay JW; Drissi R
Mol Cancer Ther; 2018 Jul; 17(7):1504-1514. PubMed ID: 29654065
[TBL] [Abstract][Full Text] [Related]
4.
Mender I; Batten K; Peyton M; Vemula A; Cornelius C; Girard L; Gao B; Minna JD; Shay JW
Cancer Res; 2020 Mar; 80(5):929-936. PubMed ID: 31948943
[TBL] [Abstract][Full Text] [Related]
5. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
7. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
13. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
14. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
[TBL] [Abstract][Full Text] [Related]
15. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
16. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Ziegler DS; Keating J; Kesari S; Fast EM; Zawel L; Ramakrishna N; Barnes J; Kieran MW; Veldhuijzen van Zanten SE; Kung AL
Neuro Oncol; 2011 Aug; 13(8):820-9. PubMed ID: 21724651
[TBL] [Abstract][Full Text] [Related]
17. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
18. The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.
Zhu W; Zhao H; Xu F; Huang B; Dai X; Sun J; Nyalali AMK; Zhang K; Ni S
BMC Cancer; 2021 Jun; 21(1):664. PubMed ID: 34082742
[TBL] [Abstract][Full Text] [Related]
19. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
[No Abstract] [Full Text] [Related]
[Next] [New Search]